Oncology — MCQs
On this page
A 60-year-old woman with heart failure and normal renal function is started on furosemide 80 mg/day. She experiences a good diuretic response with the medication. A few weeks later, she reports feeling unwell with fatigue and muscle weakness, although her heart failure symptoms have improved. What is the most likely explanation for her muscle weakness?
Hypercalcemia in the setting of squamous cell carcinoma of the esophagus is mainly due to which of the following?
What is the standard treatment for Hodgkin lymphoma?
Which of the following is NOT a feature of superior vena cava syndrome?
What is the standard treatment regimen for Hodgkin's lymphoma?
A 68-year-old woman presents with new symptoms of burning when voiding. She has no fever, chills, or back discomfort. Her urinalysis reveals numerous white cells and bacteria. Which of the following medical comorbidities is most likely to coexist in this patient?
Ten days after a kidney transplant, a 32-year-old man returns to the hospital with symptoms of fever and decreased urine output. He reports no cough, sputum, or dysuria. An ultrasound of the transplant kidney shows allograft enlargement. Which of the following is the most likely diagnosis?
A 63-year-old woman with well-controlled Type 2 diabetes mellitus presents with peripheral neuropathy in the feet and non-proliferative retinopathy. Urinalysis is positive for proteinuria. Which of the following treatments is most likely to attenuate the course of renal disease?
A 62-year-old man with a history of hypertension and stage-III squamous cell carcinoma of the lung who recently completed chemotherapy presents with sudden onset of right calf swelling and pain for 2 days. He denies trauma or recent travel and has no prior history of blood clots. Physical examination reveals a tender swelling of the right calf without erythema. His D-dimer is elevated at 640 ng/mL, and venous Doppler confirms occlusive thrombi in the deep veins of the right leg. A plan is made to initiate anticoagulation for 6 months. What is the drug of choice for anticoagulation in this patient?
What is the most common malignancy observed in individuals undergoing immunosuppressive therapy?
Oncology Indian Medical PG Practice Questions and MCQs
Question 71: A 60-year-old woman with heart failure and normal renal function is started on furosemide 80 mg/day. She experiences a good diuretic response with the medication. A few weeks later, she reports feeling unwell with fatigue and muscle weakness, although her heart failure symptoms have improved. What is the most likely explanation for her muscle weakness?
- A. Hyponatremia
- B. Hypernatremia
- C. Hypokalemia (Correct Answer)
- D. Hyperkalemia
Explanation: **Explanation:** The correct answer is **Hypokalemia (Option C)**. **Mechanism:** Furosemide is a potent **loop diuretic** that inhibits the Na+/K+/2Cl- symporter in the thick ascending limb of the Loop of Henle. By increasing the delivery of sodium and fluid to the distal nephron, it stimulates the renin-angiotensin-aldosterone system (RAAS). Aldosterone acts on the principal cells of the collecting duct to reabsorb sodium in exchange for secreting potassium and hydrogen ions into the urine. This "distal delivery" effect leads to significant urinary potassium wasting. Hypokalemia causes hyperpolarization of muscle cell membranes, leading to symptoms of **fatigue, muscle weakness, and cramps.** **Analysis of Incorrect Options:** * **Hyponatremia (A):** While loop diuretics can cause hyponatremia, it is much more common with Thiazides. In this clinical context, muscle weakness following diuretic use is a classic presentation of potassium depletion. * **Hypernatremia (B):** Diuretics typically cause loss of both water and solutes; they do not typically cause a rise in serum sodium unless there is profound dehydration with inadequate water intake. * **Hyperkalemia (D):** This is a side effect of potassium-sparing diuretics (e.g., Spironolactone) or ACE inhibitors, not loop diuretics. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolic Profile of Loop Diuretics:** Hypokalemic, hypochloremic metabolic alkalosis (due to H+ loss) and hypocalcemia ("Loops lose calcium"). * **ECG Findings in Hypokalemia:** Flattened T-waves, prominent **U-waves**, and ST-segment depression. * **Drug Interaction:** Hypokalemia potentiates **Digoxin toxicity**, a critical consideration in heart failure patients. * **Ototoxicity:** Furosemide can cause dose-dependent hearing loss, especially when given intravenously or with other ototoxic drugs (e.g., Aminoglycosides).
Question 72: Hypercalcemia in the setting of squamous cell carcinoma of the esophagus is mainly due to which of the following?
- A. Bone metastasis
- B. Calcitonin excess
- C. Parathormone excess
- D. Parathormone-related peptide secretion (Correct Answer)
Explanation: Explanation: Hypercalcemia of malignancy is a common paraneoplastic syndrome, and in the context of **Squamous Cell Carcinoma (SCC)**—whether of the esophagus, lung, or head and neck—the most common mechanism is **Humoral Hypercalcemia of Malignancy (HHM)**. **1. Why Option D is Correct:** The tumor cells secrete **Parathyroid Hormone-related Protein (PTHrP)**. PTHrP mimics the action of PTH by binding to the same PTH-1 receptors in the bone and kidneys [1]. This leads to increased osteoclastic bone resorption and increased renal calcium reabsorption, resulting in systemic hypercalcemia [1]. Unlike true hyperparathyroidism, the endogenous PTH levels in these patients are typically suppressed [1]. **2. Why Other Options are Incorrect:** * **Option A (Bone metastasis):** While local osteolytic hypercalcemia occurs in cancers like breast cancer or multiple myeloma, it is less common than PTHrP secretion in esophageal SCC. * **Option B (Calcitonin excess):** Calcitonin actually *lowers* serum calcium levels. It is a marker for Medullary Thyroid Carcinoma, not SCC. * **Option C (Parathormone excess):** Ectopic production of true PTH by non-endocrine tumors is extremely rare. Hypercalcemia in malignancy is almost always due to the "related peptide" (PTHrP), not the hormone itself. **Clinical Pearls for NEET-PG:** * **Most common cause of HHM:** PTHrP secretion (associated with SCC of lung, esophagus, and cervix). * **1,25-dihydroxyvitamin D (Calcitriol) excess:** This is the mechanism for hypercalcemia in **Lymphomas** and granulomatous diseases (Sarcoidosis). * **Laboratory Findings in HHM:** High Calcium, Low PTH, High PTHrP, and Low/Normal Vitamin D levels. * **Treatment of Choice:** Aggressive IV hydration with Normal Saline, followed by IV Bisphosphonates (e.g., Zoledronic acid).
Question 73: What is the standard treatment for Hodgkin lymphoma?
- A. The ABVD regimen is commonly used. (Correct Answer)
- B. Sterility is a common side effect of the ABVD regimen.
- C. A WBC count greater than 16 x 10^9/L is considered a good prognostic factor.
- D. None of the above.
Explanation: **Explanation:** **1. Why Option A is Correct:** The **ABVD regimen** (Adriamycin, Bleomycin, Vinblastine, and Dacarbazine) is the current gold standard for both early and advanced-stage Hodgkin Lymphoma (HL). It is preferred over older regimens like MOPP because it is highly effective, better tolerated, and associated with a significantly lower risk of secondary malignancies (like leukemia) and infertility. **2. Why Other Options are Incorrect:** * **Option B:** Unlike the older MOPP regimen (Mustine, Oncovin, Procarbazine, Prednisolone), **ABVD does not typically cause permanent sterility**. This is a major clinical advantage, as HL often affects young patients of reproductive age. * **Option C:** According to the **Hasenclever International Prognostic Index (IPI)** for advanced HL, a **WBC count ≥ 15 x 10⁹/L** is actually a **poor prognostic factor**, not a good one [1]. Other poor prognostic factors include age ≥ 45, male sex, Stage IV disease, Albumin < 4 g/dL, Hemoglobin < 10.5 g/dL, and Lymphopenia (< 0.6 x 10⁹/L). **3. High-Yield Clinical Pearls for NEET-PG:** * **Bleomycin Toxicity:** Monitor for **pulmonary fibrosis**; avoid high inspired oxygen concentrations during surgery. * **Adriamycin (Doxorubicin):** Associated with dose-dependent **cardiotoxicity** (dilated cardiomyopathy). * **Reed-Sternberg Cells:** The diagnostic hallmark of HL, typically expressing **CD15 and CD30** (except in the Nodular Lymphocyte Predominant subtype, which is CD20+) [1]. * **Staging:** The **Ann Arbor Staging System** (modified by Cotswolds) is used, with PET-CT being the preferred modality for initial staging and response assessment (Deauville Criteria) [1].
Question 74: Which of the following is NOT a feature of superior vena cava syndrome?
- A. Facial swelling
- B. Hoarseness
- C. Aggravation of symptoms in the supine position (Correct Answer)
- D. Syncope
Explanation: ### Explanation Superior Vena Cava (SVC) syndrome results from the obstruction of blood flow through the SVC, most commonly due to malignancy (e.g., Small Cell Lung Cancer, Non-Hodgkin Lymphoma). **Why Option C is the Correct Answer:** The statement "Aggravation of symptoms in the supine position" is **incorrect** regarding SVC syndrome. In fact, symptoms typically **improve** or remain unchanged in the supine position compared to leaning forward. The classic clinical sign is the **Pemberton maneuver**, where elevation of the arms above the head (which mimics a "crowding" effect at the thoracic inlet) leads to facial flushing, cyanosis, and respiratory distress. While lying flat increases venous return, the most dramatic clinical aggravation occurs with maneuvers that further compress the thoracic inlet. **Analysis of Other Options:** * **A. Facial swelling:** This is the most common presenting feature. Obstruction leads to venous congestion in the head, neck, and upper extremities. * **B. Hoarseness:** This occurs due to laryngeal edema or compression of the recurrent laryngeal nerve by the primary tumor causing the SVC obstruction. * **D. Syncope:** Cerebral venous hypertension and decreased cardiac output (due to reduced preload) can lead to neurological symptoms, including dizziness and syncope. **NEET-PG High-Yield Pearls:** * **Most common cause:** Lung cancer (specifically Small Cell CA). * **Most common benign cause:** Iatrogenic (indwelling catheters/pacemaker wires) or Fibrosing Mediastinitis (Histoplasmosis). * **Clinical Hallmark:** "Puffiness" of the face, conjunctival suffusion, and dilated collateral veins on the upper chest wall. * **Management:** Emergency radiation is indicated for airway obstruction or cerebral edema; otherwise, stenting is the preferred palliative treatment.
Question 75: What is the standard treatment regimen for Hodgkin's lymphoma?
- A. VAD
- B. CMF
- C. ABVD (Correct Answer)
- D. CHOP
Explanation: **Explanation:** **Correct Option: C (ABVD)** The standard first-line chemotherapy for Hodgkin’s Lymphoma (HL) is the **ABVD regimen**. It consists of: * **A:** Adriamycin (Doxorubicin) – Antitumor antibiotic * **B:** Bleomycin – Glycopeptide antibiotic * **V:** Vinblastine – Vinca alkaloid * **D:** Dacarbazine – Alkylating agent This regimen is preferred over the older MOPP regimen because it is associated with a lower risk of secondary leukemia and permanent infertility. **Incorrect Options:** * **A (VAD):** (Vincristine, Adriamycin, Dexamethasone) was historically used for **Multiple Myeloma**, though it has largely been replaced by proteasome inhibitors like Bortezomib. * **B (CMF):** (Cyclophosphamide, Methotrexate, 5-Fluorouracil) is a classic adjuvant chemotherapy regimen for **Breast Cancer**. * **D (CHOP):** (Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone) is the gold-standard treatment for **Non-Hodgkin Lymphoma (NHL)**, specifically Diffuse Large B-Cell Lymphoma (DLBCL) [1]. **High-Yield Clinical Pearls for NEET-PG:** 1. **Staging:** The **Ann Arbor Staging** system is used for HL [2]. 2. **Pathognomonic Cell:** Presence of **Reed-Sternberg (RS) cells** (Owl’s eye appearance) which are CD15+ and CD30+ [2]. 3. **Specific Side Effects:** * **Bleomycin:** Pulmonary fibrosis (monitor with DLCO). * **Doxorubicin:** Cardiotoxicity (Dilated cardiomyopathy). * **Vinblastine:** Bone marrow suppression (unlike Vincristine, which is more neurotoxic). 4. **Relapsed HL:** Brentuximab Vedotin (anti-CD30 antibody-drug conjugate) is a high-yield salvage therapy option.
Question 76: A 68-year-old woman presents with new symptoms of burning when voiding. She has no fever, chills, or back discomfort. Her urinalysis reveals numerous white cells and bacteria. Which of the following medical comorbidities is most likely to coexist in this patient?
- A. anemia
- B. exercise
- C. diabetes mellitus (Correct Answer)
- D. influenza
Explanation: The patient presents with classic symptoms of an uncomplicated **Urinary Tract Infection (UTI)**: dysuria (burning on voiding), pyuria (white cells), and bacteriuria, in the absence of systemic symptoms like fever or flank pain (which would suggest pyelonephritis) [1]. **1. Why Diabetes Mellitus is the Correct Answer:** Diabetes mellitus (DM) is a major risk factor for UTIs due to several pathophysiological mechanisms: * **Glucosuria:** High glucose levels in urine provide an excellent culture medium for bacterial growth. * **Immune Dysfunction:** Hyperglycemia impairs neutrophil function (chemotaxis and adherence) and cytokine production. * **Autonomic Neuropathy:** Long-standing DM can lead to a "neurogenic bladder," causing incomplete emptying and urinary stasis, which facilitates bacterial colonization. * **Increased Adherence:** Bacteria (like *E. coli*) adhere more readily to the uroepithelial cells of diabetic patients. **2. Why the Other Options are Incorrect:** * **Anemia:** While chronic disease can cause anemia, it does not directly predispose a patient to bacterial UTIs. * **Exercise:** Physical activity is generally protective for overall health and is not a risk factor for urinary infections. * **Influenza:** This is a respiratory viral infection. While it can cause systemic malaise, it does not have a direct causal link with bacterial cystitis. **Clinical Pearls for NEET-PG:** * **Most Common Organism:** *Escherichia coli* remains the most common cause of UTI in both diabetic and non-diabetic patients. * **Emphysematous Cystitis/Pyelonephritis:** These are severe, gas-forming infections of the urinary tract seen almost exclusively in diabetic patients (Medical Emergency). * **Asymptomatic Bacteriuria:** In diabetic patients, asymptomatic bacteriuria is common but generally **not** treated unless the patient is pregnant or undergoing a urological procedure [1]. * **Klebsiella & Candida:** Diabetic patients have a higher incidence of UTIs caused by *Klebsiella* and fungal pathogens like *Candida albicans*.
Question 77: Ten days after a kidney transplant, a 32-year-old man returns to the hospital with symptoms of fever and decreased urine output. He reports no cough, sputum, or dysuria. An ultrasound of the transplant kidney shows allograft enlargement. Which of the following is the most likely diagnosis?
- A. Steroid-induced hyperglycemia
- B. Erythrocytosis
- C. Hyperacute rejection
- D. Acute rejection (Correct Answer)
Explanation: ### **Explanation** The clinical presentation of fever, graft tenderness (implied by enlargement), and decreased urine output (oliguria) occurring **10 days post-transplant** is a classic manifestation of **Acute Rejection**. [1] #### **1. Why Acute Rejection is Correct** * **Timing:** Acute rejection typically occurs within the first **few weeks to months** (usually >5 days to 6 months) after transplantation. [1] * **Pathophysiology:** It is primarily a T-cell mediated immune response (Type IV hypersensitivity) against the donor HLA antigens, though antibody-mediated components can coexist. [1] * **Clinical Features:** Patients present with systemic signs (fever), graft dysfunction (rising creatinine, decreased urine output), and physical signs of inflammation (allograft enlargement/tenderness). [1] * **Diagnosis & Management:** Gold standard is a **renal biopsy** (showing lymphocytic infiltration/tubulitis). Treatment involves high-dose corticosteroids or antithymocyte globulin (ATG). #### **2. Why Other Options are Incorrect** * **A. Steroid-induced hyperglycemia:** While common post-transplant due to immunosuppression, it presents with polyuria and thirst, not decreased urine output or graft enlargement. [2] * **B. Erythrocytosis:** This is a late complication of renal transplant (due to increased EPO production) and does not cause acute graft dysfunction or fever. * **C. Hyperacute rejection:** This occurs within **minutes to hours** of transplantation. It is caused by pre-formed anti-donor antibodies (Type II hypersensitivity) leading to immediate thrombosis and graft necrosis. [1] #### **3. High-Yield Clinical Pearls for NEET-PG** * **Hyperacute Rejection:** Minutes/Hours; Pre-formed antibodies; Type II Hypersensitivity. [2] * **Acute Rejection:** Days/Weeks; T-cells; Type IV Hypersensitivity; **Most common** type of rejection. * **Chronic Rejection:** Months/Years; Fibrosis and intimal thickening; Irreversible. * **Graft vs. Host Disease (GVHD):** Rare in solid organ transplants; common in bone marrow transplants; characterized by maculopapular rash, jaundice, and diarrhea.
Question 78: A 63-year-old woman with well-controlled Type 2 diabetes mellitus presents with peripheral neuropathy in the feet and non-proliferative retinopathy. Urinalysis is positive for proteinuria. Which of the following treatments is most likely to attenuate the course of renal disease?
- A. Calcium channel blockers
- B. ACE inhibitors (Correct Answer)
- C. Hepatic hydroxymethylglutaryl coenzyme A (HMG-CoA) inhibitors
- D. Dietary carbohydrate restriction
Explanation: **Explanation:** The patient presents with classic microvascular complications of Type 2 Diabetes Mellitus: peripheral neuropathy, retinopathy, and proteinuria (indicative of **Diabetic Nephropathy**). **Why ACE Inhibitors (ACEIs) are correct:** ACE inhibitors (e.g., Enalapril, Ramipril) are the gold standard for managing diabetic nephropathy. The underlying mechanism involves the inhibition of Angiotensin II, which normally causes **vasoconstriction of the efferent arteriole**. By dilating the efferent arteriole, ACEIs reduce **intraglomerular capillary pressure**, thereby decreasing the mechanical strain on the basement membrane and reducing proteinuria [2]. This "renoprotective" effect slows the progression to End-Stage Renal Disease (ESRD), independent of their blood pressure-lowering effects [2]. **Why other options are incorrect:** * **A. Calcium channel blockers:** While effective for hypertension, dihydropyridine CCBs (like Amlodipine) primarily dilate the *afferent* arteriole, which can potentially increase intraglomerular pressure and do not provide the same degree of renoprotection as ACEIs. * **C. HMG-CoA inhibitors (Statins):** These are essential for cardiovascular risk reduction in diabetics but have no direct role in attenuating the progression of diabetic glomerular disease. * **D. Dietary carbohydrate restriction:** While vital for glycemic control, strict carbohydrate restriction alone does not reverse established proteinuria or provide the hemodynamic benefits required to halt nephropathy progression [3]. **NEET-PG High-Yield Pearls:** * **First sign of Diabetic Nephropathy:** Microalbuminuria (30–300 mg/day) [1]. * **Pathognomonic finding:** Kimmelstiel-Wilson (KW) nodules on renal biopsy [1]. * **Drug of Choice:** ACE inhibitors or ARBs (Angiotensin Receptor Blockers) [2]. Note: Never combine ACEIs and ARBs due to the risk of hyperkalemia and acute kidney injury. * **SGLT2 Inhibitors:** Now also recognized as highly renoprotective in diabetic patients.
Question 79: A 62-year-old man with a history of hypertension and stage-III squamous cell carcinoma of the lung who recently completed chemotherapy presents with sudden onset of right calf swelling and pain for 2 days. He denies trauma or recent travel and has no prior history of blood clots. Physical examination reveals a tender swelling of the right calf without erythema. His D-dimer is elevated at 640 ng/mL, and venous Doppler confirms occlusive thrombi in the deep veins of the right leg. A plan is made to initiate anticoagulation for 6 months. What is the drug of choice for anticoagulation in this patient?
- A. Rivaroxaban
- B. Low-molecular-weight heparin (Correct Answer)
- C. Warfarin
- D. Low dose aspirin (81 mg/d)
Explanation: ### Explanation **Correct Answer: B. Low-molecular-weight heparin (LMWH)** The patient presents with **Cancer-Associated Thrombosis (CAT)**. In patients with active malignancy (especially lung cancer) and a newly diagnosed Deep Vein Thrombosis (DVT), **Low-molecular-weight heparin (LMWH)**, such as Enoxaparin, has traditionally been the drug of choice for long-term anticoagulation [1]. **Why LMWH is correct:** Clinical trials (e.g., the CLOT trial) demonstrated that LMWH is superior to Vitamin K antagonists (Warfarin) in preventing recurrent VTE in cancer patients without increasing the risk of major bleeding. Cancer patients often have fluctuating oral intake, drug interactions with chemotherapy, and frequent procedures requiring rapid reversal of anticoagulation—factors that make LMWH safer and more predictable than oral alternatives [1]. **Why other options are incorrect:** * **A. Rivaroxaban:** While DOACs (Rivaroxaban, Edoxaban) are now considered alternatives in some guidelines, they are associated with a higher risk of gastrointestinal (GI) and genitourinary bleeding, particularly in patients with luminal GI or squamous cell cancers [1]. LMWH remains a standard "gold-standard" answer in many traditional medical exams. * **C. Warfarin:** Warfarin is less effective in malignancy due to the "prothrombotic state" of cancer and is difficult to manage due to frequent interactions with chemotherapy and malnutrition-induced Vitamin K deficiency [2]. * **D. Low dose aspirin:** Aspirin is an antiplatelet agent, not an anticoagulant. It is insufficient for the treatment of an established occlusive DVT. **High-Yield Clinical Pearls for NEET-PG:** * **Trousseau Syndrome:** Migratory thrombophlebitis associated with visceral malignancy (most commonly pancreatic cancer) [1]. * **Duration of Therapy:** In cancer-associated DVT, anticoagulation is typically continued for at least **3–6 months** or as long as the cancer is active/under treatment. * **Preferred DOACs:** If a DOAC is used in cancer, **Apixaban** is often preferred over Rivaroxaban due to a lower observed risk of major bleeding in recent trials (CARAVAGGIO study).
Question 80: What is the most common malignancy observed in individuals undergoing immunosuppressive therapy?
- A. Lung
- B. Skin (Correct Answer)
- C. Hodgkin lymphoma
- D. Kidney
Explanation: The correct answer is **Skin (Option B)**. Immunosuppression, whether due to organ transplantation (post-transplant lymphoproliferative disorders) or chronic therapy for autoimmune diseases, significantly impairs the body's immune surveillance. This leads to a markedly increased risk of malignancies, particularly those with viral etiologies or those exacerbated by UV radiation [1]. **Why Skin is Correct:** Skin cancers are the most common malignancies in immunosuppressed patients [1]. Specifically, **Squamous Cell Carcinoma (SCC)** is the most frequent, occurring at a rate 65–250 times higher than in the general population [2]. Unlike the general population where Basal Cell Carcinoma (BCC) is more common, the **SCC:BCC ratio is reversed** in immunosuppressed individuals. The primary drivers are the loss of T-cell mediated surveillance of UV-damaged cells and the oncogenic effects of Human Papillomavirus (HPV) [1][2]. **Why other options are incorrect:** * **Lung (Option A):** While lung cancer risk is slightly elevated in transplant recipients (especially smokers), it is not the most common. * **Hodgkin Lymphoma (Option C):** Immunosuppressed patients are at a high risk for **Non-Hodgkin Lymphoma (NHL)**, particularly those associated with Epstein-Barr Virus (EBV) [1]. Hodgkin lymphoma is much less common in this demographic. * **Kidney (Option D):** Renal cell carcinoma risk is increased (especially in renal transplant recipients due to acquired cystic kidney disease), but its incidence remains lower than that of skin cancers. **NEET-PG High-Yield Pearls:** 1. **Most common malignancy overall:** Skin Cancer (SCC > BCC) [2]. 2. **Most common non-cutaneous malignancy:** Non-Hodgkin Lymphoma (NHL) [1]. 3. **Kaposi Sarcoma:** Highly associated with HHV-8 in immunosuppressed patients; it can regress if immunosuppression is reduced [1]. 4. **Cervical/Anogenital Cancers:** Increased risk due to persistent HPV infection under immunosuppression.
Practice by Chapter
Cancer Biology and Carcinogenesis
Practice Questions
Principles of Cancer Diagnosis and Staging
Practice Questions
Solid Tumor Management
Practice Questions
Hematological Malignancies
Practice Questions
Cancer Emergencies
Practice Questions
Principles of Chemotherapy, Immunotherapy and Targeted Therapy
Practice Questions
Radiation Oncology Basics
Practice Questions
Palliative Care in Oncology
Practice Questions
Cancer Screening and Prevention
Practice Questions
Paraneoplastic Syndromes
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free